Nav: Home

C-Path and CHDI establish a consortium to expedite approval of HD therapeutics

October 31, 2016

TUCSON, Arizona, October 31, 2016 -- Critical Path Institute (C-Path) and CHDI Foundation, Inc., are collaborating to set up a broad-based consortium that will more clearly define regulatory pathways leading to the approval of Huntington's disease (HD) therapeutics. The HD Regulatory Science Consortium (HD-RSC) will bring together participants from within and without the HD community to advance drug development tools (DDTs, such as biomarkers and clinical outcome assessments) for regulatory endorsement and to facilitate clinical data standardization and collaboration. These DDTs will be made publicly available to help expedite and de-risk the drug-development pathway, speed the time to drug approval, and offer further incentive to drug developers to enter the HD sphere.

This regulatory focus is in response to the US Food and Drug Administration's (FDA) Guidance for Industry and FDA Staff - Qualification Process for Drug Development Tools. Such tools would potentially accelerate the drug approval process. Among the consortium's specific projects will be the regulatory qualification of biomarkers and outcome measures, and the development of a clinical trial simulator. The HD-RSC will also work in partnership with the Clinical Data Interchange Standards Consortium (CDISC) to develop therapeutic area data standards, and then centrally warehouse shared data as the foundation for these and other activities.

C-Path will manage the day-to-day activities of the HD-RSC, which is expected to first meet in Q2 2017. CHDI has provided planning and start-up funds.

"We support and share C-Path's model of collaborative initiatives to accelerate drug development," says Robi Blumenstein, President of CHDI Management, Inc. "The need for C-Path's expertise in consortium building and regulatory science has become increasingly apparent as our community sees a number of high-quality therapeutic programs approach the clinic."

Through the pre-competitive consortium approach, CHDI, C-Path, and other stakeholders can share data and knowledge, avoid duplication of effort, and collaborate in innovative ways so that scientific advances can be translated into therapeutics as efficiently as possible.

"One of the fundamental challenges to drug development for a genetically predetermined disease such as HD is shifting the paradigm for drug approval, so that we can intervene as early as possible; ideally, this would eventually be before any overt symptom onset," says Martha Brumfield, PhD, C-Path president and CEO. "For quantitative analytical approaches to address this problem, data sharing, standardization, and aggregation through a rigorously defined procedure are paramount. In this regard, C-Path's core competencies in clinical data standards development, as well as secure data management, standardization, and curation, will be tapped. These skills, combined with C-Path's track record of success in consortium building and regulatory science, and CHDI's extensive data resources and research network, provide a solid foundation for the HD-RSC's success."
About Huntington's Disease

Huntington's disease (HD) is a rare genetic neurodegenerative disorder that results in behavioral, cognitive, and motor impairments. These symptoms progressively reduce an individual's quality of life, and ultimately lead to death. HD is caused by a mutation in the huntingtin gene, which results in a toxic protein that damages neurons in the brain. Approximately one person in 10,000 carries the mutated huntingtin gene, and each child of a parent with a mutation has a 50% chance of inheriting the mutation. Current HD therapies only manage the severity of symptoms; there are no approved treatments to slow the progression of HD.

About CHDI

CHDI Foundation, Inc., is a privately funded nonprofit biomedical research organization that is exclusively dedicated to rapidly developing therapies that slow the progression of Huntington's disease. As a collaborative enabler, CHDI seeks to bring the right partners together to identify and address critical scientific issues and move drug candidates to clinical evaluation as quickly as possible. CHDI scientists work closely with a network of more than 700 researchers in academic and industrial laboratories and clinical sites around the world in the pursuit of these novel therapies, providing strategic scientific direction to ensure that our common goals remain in focus. More information about CHDI can be found at

About C-Path

Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 with public and private philanthropic support from the Arizona community, Science Foundation Arizona, and the US Food and Drug Administration (FDA). C-Path's mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established 12 global, public-private partnerships that currently include over 1,450 scientists from government and regulatory agencies, academia, patient advocacy organizations, and dozens of major pharmaceutical companies. C-Path is headquartered in Tucson, Arizona. For more information, visit

The Critical Path Institute (C-Path)

Related Drug Development Articles:

Drug design strategy boosts the odds against resistance development
A new rational drug design technique that uses a powerful computer algorithm to identify molecules that target different receptor sites on key cellular proteins could provide a new weapon in the battle against antibiotic resistance, potentially tipping the odds against the bugs.
Pulmonary Thrombosis-on-a-Chip provides new avenue for drug development
Researchers at the Wyss Institute have engineered a model of human pulmonary thrombosis using its Organ-on-a-Chip platform that mimics in vivo blood clot formation and confirms the transmission of inflammatory signals from the pulmonary epithelium to the vascular endothelium, providing a new model for investigation and treatment/prevention of pulmonary blood clots.
Space station crew cultivates crystals for drug development
Crew members aboard the International Space Station will begin conducting research this week to improve the way we grow crystals on Earth.
UQ opens new era in cancer research and drug development
New cancer-fighting drugs could emerge from The University of Queensland in coming years, thanks to a state-of-the-art imaging facility opened today.
New center to address antimicrobial drug development challenge
A state-of-the-art research center to help accelerate the development of new antibiotics is set to be established by the University of Liverpool.
New drug screening system could help speed development of a cure for HPV
Scientists have used genetic engineering techniques to develop a new system that could aid identification of potential drug targets and treatments for human papillomavirus (HPV) infection, according to a PLOS Pathogens study.
Structure of atypical cancer protein paves way for drug development
A team of researchers from Case Western Reserve University School of Medicine has helped uncover the elusive structure of a cancer cell receptor protein that can be leveraged to fight disease progression.
A new direction in ophthalmic development: Nanoparticle drug delivery systems
Most ophthalmic diseases are usually treated with topically administered drug formulations (e.g. eye drops).
IUPUI chemists develop new technique that could speed drug development
Indiana University-Purdue University Indianapolis chemists have devised new molecular binding technique to substantially speed up the process of synthesizing new compounds for use as human or animal drugs.
New enzyme-mapping advance could help drug development
Scientists at MIT and the University of São Paulo in Brazil have identified the structure of an enzyme that could be a good target for drugs combatting three diseases common in the developing world.

Related Drug Development Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Climate Crisis
There's no greater threat to humanity than climate change. What can we do to stop the worst consequences? This hour, TED speakers explore how we can save our planet and whether we can do it in time. Guests include climate activist Greta Thunberg, chemical engineer Jennifer Wilcox, research scientist Sean Davis, food innovator Bruce Friedrich, and psychologist Per Espen Stoknes.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...